Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6550
    +0.0027 (+0.41%)
     

  • OIL

    83.71
    +0.14 (+0.17%)
     

  • GOLD

    2,359.40
    +16.90 (+0.72%)
     

  • Bitcoin AUD

    98,307.22
    +642.29 (+0.66%)
     

  • CMC Crypto 200

    1,388.89
    -7.64 (-0.55%)
     

  • AUD/EUR

    0.6094
    +0.0021 (+0.34%)
     

  • AUD/NZD

    1.0982
    +0.0025 (+0.23%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,110.85
    +31.99 (+0.40%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,056.18
    +138.90 (+0.78%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Lumos Pharma to Participate in December Investor Conferences

Lumos Pharma, Inc.
·2-min read

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in December:

Piper Sandler Healthcare Conference

Date:

Monday, November 23, 2020

What:

Fireside chat with Lumos Pharma management

Management will host virtual one-on-one meetings during the conference on Wednesday, December 2, 2020. An on-demand download of the fireside chat is available as of November 23rd on the Piper Sandler conference portal and under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website.

Evercore ISI HealthCONx

Date:

Thursday, December 3, 2020

Time:

1:00-1:45PM ET

What:

Panel Discussion, “Easy Pills to Swallow: Oral Drugs for Large Endo Markets” – Chiasma, Crinetics, Lumos

Management will host virtual one-on-one meetings throughout the day on Thursday, December 3, 2020. A live webcast of the panel discussion will be available on the company’s website under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website.

Please contact your Piper Sandler and Evercore ISI sales representatives to register for these investor conferences and to schedule a virtual one-on-one meeting with the Lumos Pharma management team.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.